TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
The approval further adds to Biocon’s portfolio of complex drug products
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
